PARSIPPANY, N.J., Sept. 28 /PRNewswire/ -- Innovex, the commercialization unit of Quintiles Transnational Corp., today announced an agreement to deploy a team of specialty pharmaceutical sales representatives to promote products for one of the world's leading pharmaceutical companies.
This contract has been awarded following the success of a smaller team of Innovex specialty sales representatives who have been working with the customer company. The new team represents a significant increase in the number of Innovex sales representatives dedicated to promoting these products.
"This follow-on agreement represents a substantial expansion of our previous contract with our customer," said Tony Yost, President, Innovex North America. "Likewise, it speaks highly for Innovex's ability to recruit, train and deploy specialty sales teams with the motivation, experience and product knowledge to drive the success of our customer's medicines in virtually all major therapeutic areas."
Innovex is a leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotechnology and medical device products. Since 1996, Innovex has built more than 110 sales forces, and hired more than 13,500 sales representatives to help launch more than 160 products for leading pharmaceutical companies in the United States. For more information, visit http://www.innovex.com/ .
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Web site at http://www.quintiles.com/ .
This press release contains "forward-looking statements" regarding Quintiles that involve risks and uncertainties that could cause actual results to differ materially, including, without limitation, the risk that the market for our products and services will not grow as we expect, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter new contracts, changes in trends in the pharmaceutical industry and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.
Quintiles Transnational Corp.
CONTACT: Media Relations, Tom Fuldner, +1-919-998-2091, firstname.lastname@example.org , or Investor Relations, Greg Connors,+1-919-998-2000, or email@example.com , both of Quintiles TransnationalCorp.